Stefic Karl, Bouvin-Pley Mélanie, Braibant Martine, Barin Francis
Inserm U1259, Université de Tours, 37000 Tours, France.
CHRU de Tours, Centre National de Référence du VIH-Laboratoire Associé, 37000 Tours, France.
Vaccines (Basel). 2019 Jul 25;7(3):74. doi: 10.3390/vaccines7030074.
The HIV-1 pandemic remains a major burden on global public health and a vaccine to prevent HIV-1 infection is highly desirable but has not yet been developed. Among the many roadblocks to achieve this goal, the high antigenic diversity of the HIV-1 envelope protein (Env) is one of the most important and challenging to overcome. The recent development of broadly neutralizing antibodies has considerably improved our knowledge on Env structure and its interplay with neutralizing antibodies. This review aims at highlighting how the genetic diversity of HIV-1 thwarts current, and possibly future, vaccine developments. We will focus on the impact of HIV-1 Env diversification on the sensitivity to neutralizing antibodies and the repercussions of this continuous process at a population level.
人类免疫缺陷病毒1型（HIV-1）大流行仍然是全球公共卫生的重大负担，人们迫切需要一种预防HIV-1感染的疫苗，但目前尚未研发出来。在实现这一目标的众多障碍中，HIV-1包膜蛋白（Env）的高度抗原多样性是最重要且最具挑战性的障碍之一。广谱中和抗体的最新进展极大地增进了我们对Env结构及其与中和抗体相互作用的了解。本综述旨在强调HIV-1的基因多样性如何阻碍当前以及未来可能的疫苗研发。我们将重点关注HIV-1 Env多样化对中和抗体敏感性的影响以及这一持续过程在群体水平上的影响。
